Resetting the Hsc70-mediated lysosomal degradation of PD-L1 via a supramolecular meso peptide for the restoration of acquired anti-tumor T cell immunity
Journal of Nanobiotechnology,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Feb. 4, 2025
The
reduction
of
cellular
PD-L1
abundance
through
lysosomal
degradation
is
recognized
as
essential
for
effective
and
sustained
targeting
PD-L1-dependent
immune
evasion
in
cancer.
While
Hsc70
can
interact
with
to
promote
its
degradation,
the
overexpression
CMTM6
competitively
inhibits
this
interaction,
leading
blockade
degradation.
To
overcome
issue,
a
meso
chimeric
peptide
PEPPDL1
was
designed
specifically
bind
PD-1
binding
domain
instead
Hsc70/CMTM6
domain,
while
also
facilitate
dragging
into
Hsc70-mediated
chaperone-mediated
autophagy
(CMA),
thereby
achieving
In
order
enable
internalization
tumor
cells,
supramolecular
engineering
techniques
were
employed
terminal
modification
involving
sulfydryl
monovalent
gold
ion
(Au(I)),
both
facilitating
self-assembly
modified
nanospheres
termed
CTAC-PDL1
driven
by
aurophilic
interaction.
Furthermore,
based
on
bioinformatics
analysis
mRNA
expression
data
from
30
types
tumors
obtained
TCGA
database,
malignant
melanoma
identified
most
suitable
indication
due
specific
characteristics
immune.
As
expected,
effectively
reactivated
consequently
restored
anti-tumor
T
cell
immunity
B16F10-derived
mouse
model
maintaining
favorable
safety
profile.
Overall,
work
not
only
presents
an
alternative
approach
cancer
evasion,
but
provides
modularized
strategy
discovering
regulators
target
proteins
various
diseases.
Language: Английский
Enhancing PD-1 blockade in NSCLC: Reprogramming tumor immune microenvironment with albumin-bound statins targeting lipid rafts and mitochondrial respiration
Na Chen,
No information about this author
Zhanfeng Li,
No information about this author
Heyuan Liu
No information about this author
et al.
Bioactive Materials,
Journal Year:
2025,
Volume and Issue:
49, P. 140 - 153
Published: March 7, 2025
Language: Английский
Nano-chameleons: A review on cluster of differentiation-driven immune cell-engineered nanoarchitectonics for non-small cell lung cancer
Niharika Puri,
No information about this author
Prajakta Sahane,
No information about this author
Vivek Phatale
No information about this author
et al.
International Journal of Biological Macromolecules,
Journal Year:
2025,
Volume and Issue:
310, P. 143440 - 143440
Published: April 23, 2025
Language: Английский
The impact of pre-existing interstitial lung disease on radiation and checkpoint inhibitor pneumonitis in lung cancer patients: a systematic review and meta-analysis
Therapeutic Advances in Medical Oncology,
Journal Year:
2025,
Volume and Issue:
17
Published: May 1, 2025
Background:
Current
research
presents
conflicting
evidence
on
whether
pre-existing
interstitial
lung
disease
(ILD)
serves
as
a
risk
factor
for
radiation
pneumonitis
(RP)
and
checkpoint
inhibitor
(CIP)
in
patients
with
cancer.
Objectives:
This
study
aims
to
systematically
evaluate
the
impact
of
ILD
developing
RP
CIP
cancer
patients.
Design:
A
systematic
review
meta-analysis
was
conducted
using
random-effects
model.
Data
sources
methods:
PubMed,
Embase,
Web
Science
were
searched
identify
relevant
studies.
model
applied
estimate
incidence
compared
those
without
ILD.
Sensitivity
analyses
performed
assess
robustness
pooled
findings,
potential
publication
bias
evaluated
Begg’s
Egger’s
tests.
Results:
total
12
studies
involving
2576
included
assessment,
while
29
8037
analyzed
risk.
The
results
indicated
that
significantly
increased
any-grade
(odds
ratio
(OR):
3.63,
95%
confidence
interval
(CI):
2.26–5.83)
severe
(OR:
6.10,
CI:
2.68–13.86)
Subgroup
identified
stereotactic
body
therapy
modality
associated
lowest
these
Similarly,
higher
3.86,
2.65–5.61)
3.24,
2.07–5.07),
anti-programmed
cell
death
1
therapies
showing
highest
Conclusion:
Pre-existing
markedly
increases
both
These
findings
underscore
critical
importance
thorough
evaluation
development
personalized
treatment
strategies
mitigate
risks
prior
initiating
therapy.
Language: Английский
Editorial: Overcoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: April 5, 2024
Editorial:
Overcoming
obstacles
of
cancer
immunotherapy:
the
important
role
emerging
nanomedicine
Language: Английский